The first 60 days: Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)
Multisystem Langerhans cell histiocytosis is the severe form of this rare histiocytosis, in which the abnormal cells involve several organs at once, most dangerously the liver, spleen and bone marrow of infants. It is treated with a year of vinblastine and prednisone, with stronger drugs or BRAF-targeted tablets for children who do not respond quickly; survival is now high but late effects remain. Below, week by week, is what OnCo's record of Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Biopsy with BRAF testing; blood count, liver tests, coagulation, abdominal ultrasound, skeletal survey or whole-body MRI, pituitary assessment.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis and staging.
- RadiologistNamed in the standard of care for: Diagnosis and staging, Long-term follow-up.
- Medical oncologistNamed in the standard of care for: First line, Non-response at week six or risk-organ progression, Reactivation, Long-term follow-up.
- Transplant and cell therapy teamNamed in the standard of care for: Non-response at week six or risk-organ progression.
- Palliative and supportive care teamNamed in the standard of care for: Long-term follow-up.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Vinblastine and prednisone induction for six to twelve weeks, then continuation to twelve months in total (LCH-III); mercaptopurine added for risk-organ disease in some protocols.
- 2.Non-response at week six or risk-organ progressionHistiocyte Society evaluation and treatment guidelines; NCI PDQ
Switch to cytarabine or cladribine; intensive cladribine-cytarabine for refractory risk-organ disease; BRAF inhibitor (vemurafenib, dabrafenib) for BRAF V600E-mutant disease; reduced-intensity allogeneic transplantation in selected cases.
Repeat vinblastine-prednisone or cytarabine; targeted therapy for repeated reactivation; enrolment in LCH-IV.
Endocrine, neurological, hearing, hepatic and orthopaedic surveillance for late effects through a survivorship programme.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Risk-organ involvement at diagnosis, Response at week six, BRAF V600E in tissue and cell-free DNA, MAP2K1 and other MAPK alterations, Pituitary MRI, water deprivation testing and anterior pituitary hormones), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Multisystem Langerhans cell histiocytosis without risk-organ involvement, Multisystem Langerhans cell histiocytosis with risk-organ involvement, Refractory or non-responding multisystem Langerhans cell histiocytosis.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis and staging
- For my situation (diagnosis and staging), which of the standard options do you recommend and why?Guideline options include: Biopsy with BRAF testing; blood count, liver tests, coagulation, abdominal ultrasound, skeletal survey or whole-body MRI, pituitary assessment.
First line
- For my situation (first line), which of the standard options do you recommend and why?Guideline options include: Vinblastine and prednisone induction for six to twelve weeks, then continuation to twelve months in total (LCH-III); mercaptopurine added for risk-organ disease in some protocols.
- Am I a candidate for Vinblastine, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of LCH-III apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Non-response at week six or risk-organ progression
- For my situation (non-response at week six or risk-organ progression), which of the standard options do you recommend and why?Guideline options include: Switch to cytarabine or cladribine; intensive cladribine-cytarabine for refractory risk-organ disease; BRAF inhibitor (vemurafenib, dabrafenib) for BRAF V600E-mutant disease; reduced-intensity allogeneic transplantation in selected cases.
- Am I a candidate for Cladribine, Vemurafenib, Dabrafenib + trametinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Reactivation
- For my situation (reactivation), which of the standard options do you recommend and why?Guideline options include: Repeat vinblastine-prednisone or cytarabine; targeted therapy for repeated reactivation; enrolment in LCH-IV.
- Am I a candidate for Vinblastine, Cladribine, Vemurafenib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Long-term follow-up
- For my situation (long-term follow-up), which of the standard options do you recommend and why?Guideline options include: Endocrine, neurological, hearing, hepatic and orthopaedic surveillance for late effects through a survivorship programme.
Any stage
- Are there clinical trials I could join, for example of Dabrafenib + trametinib, Vemurafenib, LCH-III, Cobimetinib?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Targeted therapy controls but does not cure; how to stop it safely is unknown”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Neurodegenerative disease appears years later and has no proven treatment”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement): the full pageMultisystem Langerhans cell histiocytosis is the severe form of this rare histiocytosis, in which the abnormal cells involve several organs at once, most dangerously the liver, spleen and bone marrow of infants. It is treated with a year of vinblastine and prednisone, with stronger drugs or BRAF-targeted tablets for children who do not respond quickly; survival is now high but late effects remain.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Cytopenias and myelosuppression: The umbrella term for low blood counts of any kind (white cells, red cells, platelets) when treatment suppresses the bone marrow.
- BRAF V600E mutation: A single spelling change in the BRAF gene that jams a growth switch permanently on.
- Late effects and survivorship toxicity: Health problems appearing months or decades after treatment ends: heart damage, infertility, second cancers, lymphoedema, dry mouth, memory problems, weak bones.
Every term links to the glossary.